Molecular pathogenesis of chronic lymphocytic leukemia: Factors and signaling pathways regulating cell growth and survival

Journal of Molecular Medicine

Volumn 77, Issue 2, 1999, Pages 282-293

  Meinhardt, Gerold ^a,b   Wendtner, Clemens M ^a   Hallek, Michael ^a,b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Gene Center   (Germany)

Author keywords

Apoptosis; Cell growth; Chronic lymphocytic leukemia; Review; Signaling

Indexed keywords

CYCLINE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; B LYMPHOCYTE ACTIVATION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; PATHOGENESIS; PROTEIN FAMILY; REVIEW;

EID: 0033011755     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050351     Document Type: Review

References (155)

1. Digel W, Stefanic M, Schoniger W et al (1989) Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 73:1242-1246
2. Cordingley FT, Bianchi A, Hoffbrand AV et al (1988) Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1:969-971
3. van Kooten C, Rensink I, Aarden L et al (1993) Cytokines and intracellular signals involved in the regulation of B-CLL proliferation. Leuk Lymphoma 12:27-33
4. Garcia CA, Rosen A, Aguilar Santelises M et al (1993) Higher proliferative response in B-chronic lymphocytic leukemia (B-CLL) as compared to B-monoclonal lymphocytosis of undetermined significance (B-MLUS) after stimulation with Staphylococcus aureus and anti-CD40 monoclonal antibodies. Leuk Res 17:933-939
5. Ranheim EA, Kipps TJ (1993) Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177:925-935
6. Fluckiger AC, Rossi JF, Bussel A et al (1992) Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 80:3173-3181
7. Larsson LG, Carlsson M, Schena M et al (1993) Interleukin-2 enhances the production of tumor necrosis factor-alpha in activated B-type chronic lymphocytic leukemia (B-CLL) cells. Leukemia 7:226-234
8. Fluckiger AC, Garrone P, Durand I et al (1993) Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med 178:1473-1481
9. Digel W, Schmid M, Heil G et al (1991) Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 78:753-759
10. Trentin L, Zambello R, Facco M et al (1997) Interleukin-15: a novel cytokine with regulatory properties on normal and neoplastic B lymphocytes. Leuk Lymphoma 27:35-42
11. Douglas RS, Capocasale RJ, Lamb RJ et al (1997) Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 89:941-947
12. Frankfurt OS, Byrnes JJ, Villa L (1997) Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. Leuk Res 21:9-16
13. Luo HY, Rubio M, Biron G et al (1991) Antiproliferative effect of interleukin-4 in B chronic lymphocytic leukemia. J Immunother Emphasis Tumor Immunol 10:418-425
14. Reittie JE, Yong KL, Panayiotidis P et al (1996) Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 22:83-90
15. Nilsson K, Larsson LG, Soderberg O et al (1992) On the role of endogenously produced TNF-alpha and IL-6 as regulators of growth and differentiation of B-type chronic lymphocytic leukemia cells in vitro. Curr Top Microbiol Immunol 182:271-277
16. Francia di Celle P, Mariani S, Riera L et al (1996) Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 87:4382-4389
17. Fluckiger AC, Durand I, Banchereau J (1994) Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 179:91-99
18. Itoh K, Hirohata S (1995) The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 154: 4341-4350
19. Jurlander J, Lai CF, Tan J et al (1997) Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 89:4146-4152
20. Chaouchi N, Wallon C, Goujard C et al (1996) Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 87:1022-1029
21. Buschle M, Campana D, Carding SR et al (1993) Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 177:213-218
22. Menzel T, Rahman Z, Calleja E et al (1996) Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87:1056-1063
23. Osorio LM, De Santiago A, Aguilar-Santelises M et al (1997) CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 89:2833-2841
24. Mainou Fowler T, Craig VA, Copplestone JA et al (1994) Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4. Blood 84:2297-2304
25. Robertson MJ, Manley TJ, Pichert G et al (1995) Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17:51-61
26. Boussiotis VA, Pangalis GA (1988) Randomized clinical trial with alpha 2b-interferon in 26 stage A untreated B-chronic lymphocytic leukemia patients. Nouv Rev Fr Hematol 30:471-473
27. Ferrara F, Rametta V, Mele G et al (1992) Recombinant interferon-alpha 2 a as maintenance treatment for patients with advanced stage chronic lymphocytic leukemia responding to chemotherapy. Am J Hematol 41:45-49
28. Langenmayer I, Nerl C, Knauf W et al (1996) Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study. Br J Haematol 94:362-369
29. Panayiotidis P, Ganeshaguru K, Jabbar SA et al (1994) Alpha-interferon (alpha-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro. Br J Haematol 86:169-173
30. Jewell AP (1996) Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 21:43-47
31. Lagneaux L, Delforge A, Bron D et al (1997) Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-b receptors. Br J Haematol 97:612-620
32. Lagneaux L, Delforge A, Bron D et al (1995) Comparative analysis of cytokines released by bone marrow stromal cells from normal donors and B-cell chronic lymphocytic leukemic patients. Leuk Lymphoma 17:127-133
33. Van Noesel CJ, Brouns GS, Schijndel GM van et al (1992) Comparison of human B cell antigen receptor complexes: membrane-expressed forms of immunoglobulin (Ig)M, IgD, and IgG are associated with structurally related heterodimers. J Exp Med 175:1511-1519
34. Sanchez M, Misulovin Z, Burkhardt AL et al (1993) Signal transduction by immunoglobulin is mediated through Ig alpha and Ig beta. J Exp Med 178:1049-1055
35. Yamanashi Y, Kakiuchi T, Mizuguchi J et al (1991) Association of B cell antigen receptor with protein tyrosine kinase Lyn. Science 251:192-194
36. Burkhardt AL, Brunswick M, Bolen JB et al (1991) Anti-immunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proc Natl Acad Sci USA 88:7410-7414
37. Hutchcroft JE, Harrison ML, Geahlen RL (1991) B lymphocyte activation is accompanied by phosphorylation of a 72-kDa protein-tyrosine kinase. J Biol Chem 266:14846-14869
38. Hutchcroft JE, Harrison ML, Geahlen RL (1992) Association of the 72-kDa protein-tyrosine kinase PTK72 with the B cell antigen receptor. J Biol Chem 267:8613-8619
39. Kolanus W, Romeo C, Seed B (1993) T cell activation by clustered tyrosine kinases. Cell 74:171-183
40. Law CL, Sidorenko SP, Chandran KA et al (1994) Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex. J Biol Chem 269:12310-12319
41. Pleiman CM, Abrams C, Gauen LT et al (1994) Distinct p53/561yn and p59fyn domains associate with nonphosphorylated and phosphorylated Ig-alpha. Proc Natl Acad Sci USA 91:4268-4272
42. Lin J, Justement LB (1992) The MB-1/B29 heterodimer couples the B cell antigen receptor to multiple src family protein tyrosine kinases. J Immunol 149:1548-1555
43. Michel F, Merle Beral H, Legac E et al (1993) Defective calcium response in B-chronic lymphocytic leukemia cells. Alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx. J Immunol 150:3624-3633
44. Coggeshall KM, McHugh JC, Altman A (1992) Predominant expression and activation-induced tyrosine phosphorylation of phospholipase C-gamma 2 in B lymphocytes. Proc Natl Acad Sci USA 89:5660-5664
45. Hivroz C, Geny B, Brouet JC et al (1990) Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. J Immunol 144:2351-2358
46. Justement LB, Campbell KS, Chien NC et al (1991) Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Science 252:1839-1842
47. Lankester AC, Schijndel GM van, Schoot CE van der et al (1995) Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 86:1090-1071
48. Aguilar Santelises M, Mellstedt H, Jondal M (1994) Leukemic cells from progressive B-CLL respond strongly to growth stimulation in vitro. Leukemia 8:1146-1152
49. Zupo S, Isnardi L, Megna M et al (1996) CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 88:1365-1374
50. Thompson AA, Talley JA, Do HN et al (1997) Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 90:1387-1394
51. Jabbar SA, Hoffmann AV, Wickremasinghe RG (1995) Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Leuk Lymphoma 18:163-170
52. Hill CS, Treisman R (1995) Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80:199-211
53. Derijard B, Hibi M, Wu IH et al (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037
54. Schuh K, Avots A, Tony HP et al (1996) Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma 23:583-592
55. Schreck R, Rieber P, Bäuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV. EMBO J 10:2247-2258
56. 2+-dependent signal transduction pathways. J Immunol 155:4685-4691
57. June CH, Rabinovitch PS, Ledbetter JA (1987) CD5 antibodies increase intracellular ionized calcium concentration in T cells. J Immunol 138:2782-2792
58. Clipstone NA, Crabtree GR (1992) Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695
59. Lin Y-C, Brown K, Siebenlist U (1995) Activation of NF-κB requires proteolysis of the inhibitor IκB-α: signal-induced phosphorylation of IκB-α alone does not release active NF-κB. Proc Natl Acad Sci USA 92:552
60. 2+-dependent thiol protease) in erythrocytes of young and old individuals. Proc Natl Acad Sci USA 91:7879
61. Bours V, Franzoso G, Azarenko V et al (1993) The oncoprotein Bcl-3 directly transactivates through KB motifs via association with DNA-binding p50B homodimers. Cell 72:729-739
62. Choi MSK, Brine RD, Holman MJ et al (1994) Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. Immunity 1:179-187
63. Venkataraman L, Francis DA, Wang Z et al (1994) Cyclosporin-A sensitive induction of NF-AT in murine B cells. Immunity 1:189-196
64. Raab M, Yamamoto M, Rudd CE (1994) The T-cell antigen CD5 acts as a receptor and substrate for the protein-tyrosine kinase p561ck. Mol Cell Biol 14:2862-2870
65. Straus DB, Weiss A (1992) Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70:585-593
66. Tsai EY, Yie J, Thanos D et al (1996) Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 16:5232-5244
67. Gilman AG (1984) G proteins and dual control of adenylate cyclase. Cell 36:577-579
68. Olsson IL, Breitman TR (1982) Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3′:5′-monophosphate- inducing agents. Cancer Res 42:3924-3927
69. Peracchi M, Lombardi L, Maiolo AT et al (1983) Plasma and urine cyclic nucleotide levels in patients with acute and chronic leukemia. Blood 61:429-434
70. Sheppard JR, Gormus R, Moldow CR (1977) Catecholamine hormone receptors are reduced on chronic lymphocytic leukaemic lymphocytes. Nature 269:693-695
71. Paietta E, Schwarzmeier JD (1983) Differences in beta-adrenergic receptor density and adenylate cyclase activity between normal and leukaemic leukocytes. Eur J Clin Invest 13:339-346
72. Kamp T, Liebl B, Haen E et al (1997) Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest 27:121-127
73. Hallek M, Kamp T, Haen E et al (1991) Reduced responsiveness of adenylate cyclase to forskolin in human lymphoma cells. Biochem Pharmacol 42:1329-1334
74. Green DR, Martin SJ (1995) The killer and the executioner: how apoptosis controls malignancy. Curr Opin Immunol 7:694-703
75. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the Bcl2 family and cell death. Blood 88:386-401
76. Gajewski TF, Thompson CB (1996) Apoptosis meets signal transduction: elimination of a BAD influence. Cell 87:589-592
77. Martin SJ, Green DR (1995) Protease activation during apoptosis: death by a thousand cuts? Cell 82:349-352
78. Earnshaw WC (1995) Nuclear changes in apoptosis. Curr Opin Cell Biol 7:337-343
79. Wyllie AH, Kerr JK, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68:251-306
80. Hamel W, Dazin P, Israel MA (1996) Adaptation of a simple flow cytometric assay to identify different stages during apoptosis. Cytometry 25:173-181
81. Trauth BC, Klas C, Peters AM et al (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-3015
82. Laster SM, Wood JG, Gooding LR (1988) Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 141:2629-2634
83. Lowe SW, Schmitt EM, Smith SW et al (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849
84. Bose R, Verheij M, Haimovitz-Friedman A et al (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82:405-414
85. Zhong LT, Sarafian T, Kane DJ et al (1993) bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 90:4533-4537
86. Kaufmann SH, Desnoyers S, Ottaviano Y et al (1993) Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53:3976-3985
87. Rao L, Perez D, White E (1996) Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135:1441-1455
88. Cryns VL, Bergeron L, Zhu H et al (1996) Specific cleavage of alpha-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1 beta-converting enzyme/Ced-3 protease distinct from the poly (ADP-ribose) polymerase protease. J Biol Chem 271:31277-31282
89. Mashima T, Naito M, Noguchi K et al (1997) Actin cleavage by CPP-32/apopain during the development of apoptosis. Oncogene 14:1007-1012
90. An B, Dou QP (1996) Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res 56:438-442
91. Chen WD, Otterson GA, Lipkowitz S et al (1997) Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 14:1243-1248
92. Tewari M, Beidler DR, Dixit VM (1995) CrmA-inhibitable cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem 270:18738-18741
93. Le Romancer M, Cosulich SC, Jackson SP et al (1996) Cleavage and inactivation of DNA-dependent protein kinase catalytic subunit during apoptosis in Xenopus egg extracts. J Cell Sci 109:3121-3127
94. Wang X, Zelenski NG, Yang J et al (1996) Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15:1012-1020
95. Emoto Y, Manome Y, Meinhardt G et al (1995) Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14:6148-6156
96. Ray CA, Black RA, Kronheim SR et al (1992) Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 69:597-604
97. Bump NJ, Hackett M, Hugunin M et al (1995) Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 269:1885-1888
98. Ellis HM, Horvitz HR (1986) Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817-829
99. Cerretti DP, Kozlosky CJ, Mosley B et al (1992) Molecular cloning of the interleukin-1 beta converting enzyme. Science 256:97-100
100. Takahashi A, Earnshaw WC (1996) ICE-related proteases in apoptosis. Curr Opin Genet Dev 6:50-55
101. Li P, Allen H, Banerjee S et al (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401-511
102. Bellosillo B, Dalmau M, Colomer D et al (1997) Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 89:3378-3384
103. H on chromosome 14 and near a transcriptional unit on 18. Cell 41:889
104. Farrow SN, Brown R (1996) New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev 6:45-49
105. Reed JC (1995) Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451-473
106. Boise LH, Gonzalez-Garcia M, Postema CE et al (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608
107. Nunez G, London L, Hockenbery D et al (1990) Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602-3610
108. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
109. Yang E, Zha J, Jockel J et al (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-291
110. Wang K, Yin XM, Chao DT et al (1996) BID: a novel BH3 domain-only death agonist. Genes Dev 10:2859-2869
111. Rao L, Debbas M, Sabbatini P et al (1992) The adenovirus E1 a proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89:7742-7746 (published erratum appears in Proc Natl Acad Sci USA 89:9974)
112. Sedlak TW, Oltvai ZN, Yang E et al (1995) Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 92:7834-7838
113. Lin EY, Orlofsky A, Berger MS et al (1993) Characterization of Al, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 151:1979-1988
114. Kozopas KM, Yang T, Buchan HL et al (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90:3516
115. Das R, Reddy EP, Chatterjee D et al (1996) Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma. Oncogene 12:947-951
116. Haldar S, Jena N, Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-4511
117. Zha J, Harada H, Yang E et al (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X (L) Cell 87:619-628
118. Korner I, Weber-Nordt R, Pfaff P et al (1997) Analysis of a regulatory element in the 5′-untranslated region of the bcl-2 gene. FEBS Lett 406:31-32
119. Hanada M, Delia D, Aiello A et al (1993) bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820-1828
120. Molica S, Mannella A, Dattilo A et al (1996) Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis. Haematologica 81:302-309
121. Morabito F, Filangeri M, Callea I et al (1997) Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 82:16-20
122. Konig A, Menzel T, Lynen S et al (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258-265
123. Dancescu M, Rubio Trujillo M, Biron G et al (1992) Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176:1319-1326
124. Blagosklonny MV, Giannakakou P, el Deiry WS et al (1997) Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130-135
125. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233
126. Thomas A, El Rouby S, Reed JC et al (1996) Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12:1055-1062
127. Yonish-Rouach E, Resnitzky D, Lotem J et al (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347
128. Shaw P, Bovey R, Tardy S et al (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4459
129. Deng C, Zhang P, Harper JW et al (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684
130. Brugarolas J, Chandrasekaran C, Gordon JI et al (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557
131. Kastan MB, Zhan Q, el Deiry WS et al (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597
132. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
133. Knudson CM, Tung KS, Tourtellotte WG et al (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99
134. Buckbinder L, Talbott R, Velasco Miguel S et al (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649
135. Owen Schaub LB, Zhang W, Cusack JC et al (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040
136. Miyashita T, Krajewski S, Krajewska M et al (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805
137. Gaidano G, Ballerini P, Gong JZ et al (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417
138. el Rouby S, Thomas A, Costin D et al (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of Mdr1/Mdr3 gene expression. Blood 82:3452-3459
139. Wattel E, Preudhomme C, Hecquet B et al (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157
140. Gaidano G, Newcomb EW, Gong JZ et al (1994) Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am J Pathol 144:1312-1319
141. Döhner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589
142. Newcomb EW (1995) P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 17:211-221
143. Newcomb EW, Rao LS, Giknavorian SS et al (1995) Alterations of multiple tumor suppressor genes (p53 (17p13) p16INK4 (9p21) and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol Carcinog 14:141-146
144. Ichikawa A, Hotta T, Saito H (1993) Mutations of the p53 gene in B-cell lymphoma. Leuk Lymphoma 11:21-25
145. Fenaux P, Preudhomme C, Lai JL et al (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 6:246-250
146. Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Overlap of the p53-responsive element and cAMP-responsive element in the enhancer of human T-cell leukemia virus type I. Cell 69:1237-1245
147. Dubs-Poterszman MC, Tocque B, Wasylyk B (1995) MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11:2445-2449
148. Watanabe T, Hotta T, Ichikawa A et al (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:3158-3165
149. Delmer A, Ajchenbaum-Cymbalista F, Tang R et al (1995) Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85:2870-2876
150. Ando K, Ajchenbaum-Cymbalista F, Griffin JD (1993) Regulation of G1/S transition by cyclins D2 and D3 in hematopietic cells. Proc Natl Acad Sci USA 90:9571
151. Lai C-F, Ripperger J, Morella KK et al (1996) Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem 271:13968-13975
152. Frank DA, Mahajan S, Ritz J (1997) B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100:3140-3148
153. Huang P, Wright S (1997) Induction of apoptosis by nucleoside analogs. In: Nucleoside analogs in cancer therapy. Cheson B, Keating M, Plunkett W (eds) Marcell Dekker, New York, pp 37-73
154. Goodman MG, Spinosa JC, Saven A et al (1996) New perspectives on the approach to chronic lymphocytic leukemia. Leuk Lymphoma 22:1-10
155. Goodman MG, Wormsley SB, Spinosa JC et al (1994) Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood 84:3457-3464